Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: Problems and perspectives for immunotherapy

Journal of Molecular Medicine

Volumn 75, Issue 6, 1997, Pages 400-413

  Schendel, Dolores J ^a,c   Oberneder, Ralph ^a   Falk, Christine S ^a   Jantzer, Petra ^a   Kressenstein, Susanne ^a   Maget, Barbara ^a   Hofstetter, Alfons ^a   Riethmüller, Gert ^a   Nößner, Elfriede ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cytotoxic T lymphocytes; Immunotherapy; Lymphokine activated killer cells; Renal cell carcinoma T cell receptor

Indexed keywords

LYMPHOKINE; T LYMPHOCYTE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIGAND BINDING; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; REVIEW;

ANTIGEN-ANTIBODY REACTIONS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES, REGULATORY;

EID: 0030851392     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050125     Document Type: Review

References (119)

1. Abi-Aad AS, Belldegrun A, deKernion JB (1991) Renal cell carcinoma: physiology, diagnosis, and therapy. World J Urol 9:168-172
2. Pittman K, Selby P (1994) The management of renal cell carcinoma. Crit Rev Oncol Hematol 16:181-200
3. Guinan PD, Vogelzang NJ, Fremgen AM, Chmiel JS, Sylvester JL, Sener SF, Imperato JP (1995) Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol 153:901-903
4. Riethmuller G, Johnson JP (1992) Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 4:647-655
5. Oliver RT, Nethersell AB, Bottomley JM (1989) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 63:128-131
6. De Riese W, Allhoff E, Kirchner H, Stief CG, Atzpodien J, Maschek H, Jonas U (1991) Complete spontaneous regression in metastatic renal cell carcinoma - an update and review. World J Urol 9:184-191
7. Abubakr Y, Chou ATH, Redman BG (1994) Spontaneous remission of renal cell carcinoma: a case report and immunological correlates. J Urol 152:156-157
8. Angus R, Collins CMP, Symes MO (1993) Expression of major histocompatibility complex (MHC) antigens and their loss on culture in renal carcinoma. Eur J Cancer 26A:2158-2160
9. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491-499
10. Pantel K, Schlimok G, Kutter D, Schaller G, Genz, T. Wiebecke B, Backmann R, Funke I, Riethmuller G (1991) Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51:4712-4715
11. Belldegrun A, Figlin R, Haas G, deKernion J (1991) Immunotherapy for metastic renal-cell carcinoma. World J Urol 9:157-159
12. Rosenberg SA (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199
13. Whittington R, Faulds D (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446-514
14. Rosenberg S, Yang AJC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913
15. Angus R, Collins CMP, Symes MO (1993) The effect of a and γ interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro. Eur J Cancer 29A:1879-1885
16. Gutterman JU (1994) Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci USA 91:1198-1205
17. Krown SE (1987) Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 59:647
18. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, deKernion J, Figlin R (1993) Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol 150:1384-1390
19. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous α interferon treatment. Cancer Res 53:4020-4025
20. Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:344-348
21. Lorenz J, Wilhelm K, Kessler M, Peschel C, Schwulera U, Lissner R, Struff WG, Huland R, Huber C, Aulitzky WE (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 2:1115-1122
22. Toetterman T, Häyry HP, Saksela E, Timonen T, Eklund B (1978) Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II Functional investigation of the infiltrating inflammatory cells. Eur J Immunol 8:872-875
23. Heinemann D, Smith PJB, Symes MO (1987) Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas. Br J Cancer 56:433-437
24. Stoerkel S, Keymer R, Steinbach E, Thoenes W (1992) Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res 378:217-223
25. Stoerkel SE (1995) Classification of renal cell carcinoma based on morphologic and cytogenetic correlations. In: Bukowski RM, Finke JH, Klein EA (eds) Biology of renal cell carcinoma. Springer, Berlin Heidelberg New York, pp 3-12
26. Farace F, Angevin E, Escudier B, Caignard A, Dietrich P-Y, Genevee C, Hercend T, Triebel F (1993) Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. Int J Cancer 54:741-747
27. Filgueira L, Zuber M, Merlo A, Harder F, Heberer M, Spagnoli GC (1993) Effects of different culture protocols on the expression of discrete T-cell receptor variable regions in human tumour infiltrating lymphocytes. Eur J Cancer 29A: 1754-1760
28. Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL (1993) Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 53:4745-4749
29. Gaudin C, Dietrich P-Y, Robache S, Guillard M, Escudier B, Lacombe M-JT, Kumar A, Triebel F, Caignard A (1995) In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res 55:685-690
30. Jantzer P, Oberneder R, Maget B, Schendel DJ (1995) Recruitment of MHC-restricted cytotoxic T lymphocytes specific for renal cell carcinoma to the tumor in situ. In: RM Bukowski, JH Finke, EA Klein (eds) Biology of renal cell carcinoma. Springer, Berlin Heidelberg New York, pp 84-93
31. Caignard A, Guillard M, Gaudin C, Escudier B, Triebel F, Dietrich P-Y (1996) In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 66:564-570
32. Puisieux I, Bain I, Merrouche Y, Malacher P, Kourilsky P, Even J, Favrot M (1996) Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 66:201-2088
33. Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48:206-214
34. Alexander J, Rayman P, Edinger M, Connelly R, Tubbs R, Bukowski R, Pontes E, Finke J (1990) TIL from renal-cell carcinoma: Restimulation with tumor influences proliferation and cytolytic activity. Int J Cancer 45:119-124
35. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200-205
36. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363-2370
37. Kim T-Y, von Eschenbach AC, Filaccio MD, Hayakawa K, Parkinson DR, Balch CM, Itoh K (1990) Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res 50:5263-5268
38. Koo AS, Tso C-L, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A (1991) Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 10:347-354
39. + T cell line. J Immunother 11:1-11
40. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofsteuer A, Riethmuller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209-4220
41. Bernhard H, Karbach J, Wölfel T, Busch P, Störkel S, Stöckle M, Wölfel C, Seliger B, Huber C, Meyer zum Büschenfelde K-H, Knuth A (1994) Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 59:837-842
42. Bernhard H, Jäger E, Maeurer MJ, Meyer zum Büschenfelde KH, Knuth A (1996) Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Tissue Antigens 48:22-31
43. Anichini A, Fossati G, Parmiani G (1987) Clonal analysis of cytolytic T-cell response to human tumors. Immunol Today 12:385-389
44. Rosenberg S (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 75:595-603
45. Itoh K, Tilden AB, Balch CM (1986) Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol 136:3910-3915
46. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193-1205
47. Phillips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814-825
48. Sondel PS, Hank JA, Kohler PC, Chen BP, Minkoff DZ, Molenda JA (1986) Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 137:502-511
49. Parmiani G (1990) An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 11:113-115
50. Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K (1991) Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother 10:313-325
51. Jemma C, Cignetti A, Geuna M, Caretto P, Vai S, Forni G (1991) In vitro and in vivo comparison of the activity of human lymphokine-activated killer (LAK) cells and adherent LAK cells. J Immunother 10:189-199
52. Sedlmayr P, Rabinowich H, Elder EM, Ernstoff MS, Kirkwood JM, Herberman RB, Whiteside TL (1991) Depressed ability of patients with melanoma and renal cell carcinoma to generate adherent lymphokine-activated killer cells. J Immunother 10:336-346
53. + T lymphocytes, and NK cells. J Immunol 149:3495-3502
54. O'Shea J, Ortaldo JR (1992) The biology of natural killer cell: insights into the molecular basis of function. In: CE. Lewis, JO McGee (eds) The natural killer cell. Oxford University Press, New York, pp 2-40
55. Trinchieri G (1994) Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 180:417-421
56. Bezouska K, Yuen C-T, O'Brien J, Childs RA, Chai W, Lawson AM, Drbal K, Fiserová A, Pospísil M, Feizi T (1994) Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature 372:150-157
57. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R (1993) Contribution of carbohydrate antigens sialyl Lewis a and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53:354-361
58. Colonna M (1996) Natural killer cell receptors specific for MHC class I molecules. Curr Opin Immunol 8:101-107
59. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L (1996) Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619-648
60. Piontek GE, Taniguchi K, Ljunggren HG, Gronberg A, Kiessling R, Klein G, Karre K (1985) YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol 135:4281-4288
61. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P (1989) Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 86:2361-2364
62. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995) Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2:439-449
63. Phillips JH, Chang C, Mattson J, Gumperz JE, Parham P, Lanier LL (1996) CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA-A, HLA-B, and HLA-C allotypes. Immunity 5:163
64. Falk CS, Steinle A, Schendel DJ (1995) Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells. J Exp Med 182:1005-1018
65. Phillips JH, Gumperz JE, Parham P, Lanier LL (1995) Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403-405
66. Ljunggren H-G, Kärre K (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11:237-244
67. Garrido F, Cabrera T, Lopez Nevot MA, Ruiz-Cabello F (1995) HLA class I antigens in human tumors. Adv Cancer Res 67:155-195
68. Luboldt HJ, Kubens BS, Rubben H, Grosse Wilde H (1996) Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56:826-830
69. Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM (1994) Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother 15:91-104
70. Browning M, Krausa P (1996) Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 17: 165-170
71. Marsh SGE (1996) Nomenclature for factors of the HLA system, update June 1996. Tissue Antigens 48:233
72. Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Charron D, Dupont B, Erlich HA, Fauchet R, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI (1997) Nomenclature for factors of the HLA system, 1996. Tissue Antigens 49:297-321
73. Nössner E, Schendel DJ (1997) Autologous and allogeneic tumor cell vaccines. In: T Blankenstein, Herrmann W (eds) Gene therapy: principles and applications. Chapman and Hall, Weinheim in press
74. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
75. + T cells by B7-transfected melanoma cells. Science 259:368-370
76. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523-532
77. Ramarathinam L, M Castle, Wu Y, Liu Y (1994) T cell Costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179:1205-1214
78. Yang G, Hellström KE, Hellström I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154:2794-2800
79. Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9:58-62
80. Blankenstein T, Rowley DA, Schreiber H (1991) Cytokines and cancer: experimental systems. Curr Opin Immunol 3:694-698
81. Knuth A, Wölfel T, Meyer zum Büschenfelde K-H (1991) Cellular and humoral immune responses against cancer: implications for cancer vaccines. Curr Opin Immunol 3:659-664
82. Oettgen HF (1991) Cytokines in clinical cancer therapy. Curr Opin Immunol 3:699-705
83. Pardoll DM (1993) New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719-725
84. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415
85. Davis MM, Bjorkman PJ (1988) T-cell antigen receptor genes and T-cell recognition. Nature 334:395-402
86. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA (1996) An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209-219
87. Rowen L, Koop BF, Hood L (1996) The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 727:1755-1762
88. Nitta T, Oksenberg JR, Rao NA, Steinman L (1990) Predominant expression of T cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249:672-674
89. Ebato M, Nitta T, Yagita H, Sato K, Okumura K (1994) Shared amino acid sequences in the NDβN and Nα regions of the T cell receptors of tumor-infiltrating lymphocytes within malignant glioma. Eur J Immunol 24:2987-2992
90. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE (1990) Use of the polymerase chain reaction in the quuntitation of mdr-1 gene expression. Biochemistry 29:10351-10356
91. Panzara MA, Oksenberg JR, Steinmann L (1992) The polymerase chain reaction for detection of T-cell antigen receptor expression. Curr Opin Immunol 4:205-210
92. Ferradini L, Mackensen A, Genevée C, Bosq J, Duvillard P, Avril M-F, Hercend T (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91:1183-1190
93. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini E, Farina C, Nicolini G, Wölfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G (1995) Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92:5674-5678
94. Pannetier C, Cochet M, Darche S, Casrouge A, Zoeller M, Kourilsky P (1993) The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90:4319-4323
95. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P (1994) Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153:2807-2818
96. McHeyzer-Williams MG, Davis MM (1995) Antigen-specific development of primary and memory T cells in vivo. Science 268:106-111
97. Maryanski JL, Jongeneel CV, Bucher P, Casanova J-L, Walker PR (1996) Single-cell PCR analysis of TCR repertoire selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Immunity 4:47-55
98. Rohrer JW, Coggin JH Jr (1995) CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 155:5719-5727
99. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272
100. Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C (1996) Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56:1756-1760
101. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA (1989) Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142:4520-4-526
102. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH (1993) T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:1380- 1387
103. Finke J, Kudoh S, Stanley J, Li X, Wang Q, Park J-K, Liu J, Kolenko V, Rayman P, Klein E, Tubbs R, Bukowski RM (1995) Impaired signal transduction in tumor infiltrating T cells from patients with renal cell carcinoma. In: Bukowski RM, Finke JH, Klein EA (eds) Biology of renal cell carcinoma. Springer, Berlin Heidelberg New York, pp 72-83
104. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT (1995) Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 41:111-121
105. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173
106. Kagi D, Ledermann B, Buerki K, Zinkernagel RM, Hengartner H (1996) Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14:207-232
107. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613-5616
108. Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F (1994) The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 59:752-755
109. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
110. Li X, Liu J, Park JK, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs R, Bukowski R, Finke J (1994) T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 54:5424-5429
111. Zier K, Gansbacher B, Salvatori S (1996) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immun Today 17:39-45
112. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO (1996) Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4:77-85
113. Anonymous (1996) Clinical protocols: cytokine/immunotherapy. Cancer Gene Ther 3:58-68
114. Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van den Eynde B, Uyttenhove C, Renauld J-C, Boon T (1995) Gene coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229-250
115. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Vanderspek CW, Patard JJ, Boon T, Schrier P, Vandeneynde BJ (1996) A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44:323-330
116. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert, J-M Plagne R, Deraemaeker R, Knuth A, Jaeger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885
117. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Kurbach J, Ilsemann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169
118. Schendel DJ, Wank R, Dupont B (1979) Standardization of the human in vitro cell-mediated lympholysis technique. Tissue Antigens 13:112-120
119. Shimizu Y, DeMars R (1989) Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J Immunol 142:3320-3328